2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, Illinois, US 29 May 2026 - 02 June 2026
ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?
ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.
Chiauranib extends PFS in platinum-resistant ovarian cancer, including in anti-angio–exposed patients
Chiauranib plus weekly paclitaxel significantly extends progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer, including those previously treated with anti-angiogenic agents, according to the findings of the phase III CHIPRO trial presented at ASCO 2026.
Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC
Adding low-dose pembrolizumab to chemotherapy results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with advanced non-small cell lung cancer (NSCLC), as shown in a phase 3 trial presented at ASCO 2026.
PROTEUS sets new course for prostate cancer
In the final analysis of the phase III PROTEUS trial, perioperative apalutamide + androgen deprivation therapy (APA+ADT) improves the curative success of radical prostatectomy (RP) in men with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC).
Daraxonrasib makes history in one of the deadliest cancers
Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.